Publication Name	World Journal of Clinical Cases
Manuscript ID	90957
Country	Egypt

Received	2023-12-18 13:00
Peer-Review Started	2023-12-18 13:00
To Make the First Decision
Return for Revision	2024-01-29 21:43
Revised	2024-02-10 09:30
Second Decision	2024-04-07 01:08
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-07 07:20
Articles in Press	2024-04-07 07:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-15 02:15
Publish the Manuscript Online	2024-04-25 08:14

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors
Manuscript Source	Invited Manuscript
All Author List	Mohamed Wishahi
ORCID	Author(s) ORCID Number Mohamed Wishahi http://orcid.org/0000-0002-4559-619X
Funding Agency and Grant Number
Corresponding Author	Mohamed Wishahi, MD, PhD, Professor, Surgical Oncologist, Department of Urology, Theodor Bilharz Research Institute, Embaba, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com
Key Words	Prostate cancer; Neuroendocrine carcinoma; Treatment induced neuroendocrine prostate cancer; Androgen deprivation therapy; Genetic and epigenetic factors; Castration resistant prostate cancer; De novo neuroendocrine prostate cancer
Core Tip	Neuroendocrine prostate cancer (NEPC) are aggressive metastatic tumors, and there are two distinct types. De novo NEPC, which is less than 2% of all prostate cancer, is categorized as an entity of the endocrine tumors. The other type is the treatment induced NEPC (t-NEPC) that develops in castration resistant prostate cancer (CRPC) following androgen deprivation therapy, and it is an aggressive metastatic tumor occurs in 10%-17% of patients with CRPC and metastatic cancer, with median survival of 7 months after diagnosis. Genomic, epigenetic, and transcriptional alternation has been reported to be involved in its development. Future expectations for treatment would be tumor-directed immunotherapy.
Publish Date	2024-04-25 08:14
Citation	Wishahi M. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors. World J Clin Cases 2024; 12(13): 2143-2146
URL	https://www.wjgnet.com/2307-8960/full/v12/i13/2143.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i13.2143

Full Article (PDF)	WJCC-12-2143-with-cover.pdf
Manuscript File	90957_Auto_Edited-YJP.docx
Answering Reviewers	90957-Answering reviewers.pdf
Audio Core Tip	90957-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90957-Conflict-of-interest statement.pdf
Copyright License Agreement	90957-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90957-Language certificate.pdf
Peer-review Report	90957-Peer-review(s).pdf
Scientific Misconduct Check	90957-Bing-Che XX-2.png
Scientific Editor Work List	90957-Scientific editor work list.pdf
CrossCheck Report	90957-CrossCheck report.pdf